Overview
The National Institutes of Health (NIH) is encouraging research on the causes and progression of celiac disease, earlier and more reliable diagnostics, new therapeutic targets, and better prevention and treatment strategies.
Celiac disease is an autoimmune condition triggered by dietary gluten in genetically susceptible people and affects more than 1% of the U.S. population. A strict gluten-free diet is the only known treatment, and many patients respond poorly to it. For small businesses with diagnostic or therapeutic technology, the NIH SBIR program is the route to fund this work.
Key dates and funding
- Next SBIR due dates: January 5, 2027 and April 5, 2027 (5:00 PM local time of your organization)
- Application route: NIH, CDC and FDA Parent SBIR (R43/R44), PA-27-100, Clinical Trial Optional
- Project period: normally up to 6 months for Phase I and up to 2 years for Phase II
- Topic window: NIH lists this Highlighted Topic through September 10, 2027, so it can support more than one submission cycle
Budget guidelines in PA-27-100 vary by participating Institute or Center. Total costs (direct, indirect, and fee) normally stay within these amounts:
- National Institute of Allergy and Infectious Diseases (NIAID): Phase I $700,000, Phase II $3,000,000
- National Cancer Institute (NCI): Phase I $700,000, Phase II $2,500,000
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): SBA guideline for both phases
- National Institute of Dental and Craniofacial Research (NIDCR): SBA guideline for both phases
Who is eligible?
Only United States small business concerns can apply through the NIH Parent SBIR announcement. In plain terms, your company must meet these requirements:
- A for-profit business with a place of business in the United States and no more than 500 employees, including affiliates
- Generally more than 50% owned and controlled by U.S. citizens or permanent residents, or by qualifying venture capital, hedge fund, or private equity owners under SBA rules
- The Principal Investigator is primarily employed by the small business at the time of award and for the duration of the project
- No foreign organizations, foreign components, or foreign subawards (unfunded foreign collaborators and foreign consultants are permitted)
- Companies selected for funding submit the SBA foreign affiliations disclosure during the Just-in-Time process
Focus areas by NIH Institute
NIAID: diagnosis, immunology, and new interventions
- Earlier and better diagnosis
- Immune mechanisms of disease
- Immune-modulating interventions to prevent disease or restore gluten tolerance
- Biomarkers and new research models
NCI: celiac disease and cancer
- Immune mechanisms and gut microbiome roles
- Tumor models
- Effects of immune checkpoint blockade
NIAMS: musculoskeletal and skin effects
- Skin, bone, joint, and other musculoskeletal symptoms, comorbidities, and complications
NIDCR: oral and dental manifestations
- Enamel defects, oral ulcers, and salivary and oral microbiome changes
- Links between nutrition and oral health
How to apply
NIH Highlighted Topics are not funding opportunities on their own. Small businesses apply through the NIH, CDC and FDA Parent SBIR announcement (PA-27-100) and write the application to match the interests of at least one participating Institute or Center. Read the full NIH Highlighted Topic before you start.
- Register early: SAM.gov (which issues your UEI and can take six weeks or more), Grants.gov, eRA Commons (a Signing Official plus a PI account with a linked ORCID iD), and the SBA Company Registry (proof of registration is attached to the application)
- Talk to the program officer: the topic lists a central NIAID contact plus NCI, NIAMS, and NIDCR contacts, and ORWH (which does not award grants) is interested in sex-specific factors in celiac disease when paired with an awarding Institute
- Check the budget: contact the participating Institute or Center early if you plan to request more than the SBA budget guideline
- Submit electronically: through NIH ASSIST, a system-to-system solution, or Grants.gov Workspace by 5:00 PM local time on January 5, 2027 or April 5, 2027
Is this a fit for your company?
This topic suits companies building celiac diagnostics or biomarker panels, immune-modulating or tolerance-restoring therapies, enzyme or microbiome-based approaches, or new preclinical models of the disease. A strong application ties the technology to a specific gap NIH names, such as missed diagnoses or poor response to the gluten-free diet.
If that sounds like your company, book a free funding fit call with BW&CO. Our team has helped secure $350M+ in non-dilutive funding and can tell you quickly whether this topic, and which Institute, is the right target for your January or April submission.
Frequently asked questions
Is the NIH celiac disease Highlighted Topic a funding opportunity?
No. It is an NIH Highlighted Topic, which signals scientific interest but is not a notice of funding opportunity. Small businesses apply through the NIH Parent SBIR announcement (PA-27-100), with the next due dates on January 5, 2027 and April 5, 2027.
How much NIH SBIR funding is available for celiac disease research?
Budget guidelines in PA-27-100 depend on the Institute. NIAID and NCI allow up to $700,000 for Phase I. For Phase II, NIAID allows up to $3,000,000 and NCI up to $2,500,000. NIAMS and NIDCR follow the SBA guideline.
Which NIH Institutes participate in the celiac disease topic?
NIAID, NCI, NIAMS, and NIDCR participate. ORWH also participates but does not award grants, so applications must align with at least one awarding Institute.
What celiac disease research is NIH looking for?
Research on disease causes and progression, earlier and more reliable diagnosis, biomarkers, therapeutic targets, immune-modulating interventions to prevent disease or restore gluten tolerance, and related cancer, musculoskeletal, skin, and oral health effects.
Who is eligible to apply through NIH SBIR?
U.S. for-profit small businesses with no more than 500 employees, majority owned and controlled by U.S. citizens or permanent residents (or qualifying investors under SBA rules), whose Principal Investigator is primarily employed by the company. Foreign organizations and foreign subawards are not allowed.
Can BW&CO help with an NIH SBIR application for this topic?
Yes. BW&CO helps small businesses choose the right NIH Institute, align the Specific Aims with the Highlighted Topic, and build a competitive SBIR application. The firm has helped clients secure $350M+ in non-dilutive funding. Book a free funding fit call to see if your technology is a match.